161 related articles for article (PubMed ID: 34727272)
1. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
3. Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.
Montgomery ET; Katz AWK; Duby Z; Mansoor LE; Morar NS; Naidoo K; Tsidya M; Chitukuta M; Guma V; Tenza S; Leslie J; Garcia M; Naidoo S
AIDS Behav; 2021 Jun; 25(6):1890-1900. PubMed ID: 33389318
[TBL] [Abstract][Full Text] [Related]
4. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
[TBL] [Abstract][Full Text] [Related]
5. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
Leslie J; Kiweewa F; Palanee-Phillips T; Bunge K; Mhlanga F; Kamira B; Baeten J; Katz A; Hillier S; Montgomery E;
BMC Womens Health; 2021 Apr; 21(1):175. PubMed ID: 33892693
[TBL] [Abstract][Full Text] [Related]
6. Male Partner Opinions of the Dapivirine Vaginal Ring Used During an Open-Label Extension HIV Prevention Trial in KwaZulu-Natal, South Africa.
Morar NS; Mansoor LE; Naidoo K; Katz AWK; Garcia M; Duma C; Precious Myeni NB; Tshbalala T; Naidoo S; Montgomery ET
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):127-133. PubMed ID: 36302179
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
Naidoo K; T ME; Katz AW; Morgan G; Krishnaveni R; Lydia ST; Sarita N; Leila ME
AIDS Behav; 2023 Jan; 27(1):75-81. PubMed ID: 35672549
[TBL] [Abstract][Full Text] [Related]
8. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
[TBL] [Abstract][Full Text] [Related]
9. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
10. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
[TBL] [Abstract][Full Text] [Related]
11. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
12. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
[TBL] [Abstract][Full Text] [Related]
13. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
[TBL] [Abstract][Full Text] [Related]
14. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
[TBL] [Abstract][Full Text] [Related]
15. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
16. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
[TBL] [Abstract][Full Text] [Related]
17. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
[TBL] [Abstract][Full Text] [Related]
18. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
20. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
